What is IMMNOV.ST's Intrinsic value?

Immunovia AB (publ) (IMMNOV.ST) Intrinsic Value Analysis

Executive Summary

As of May 22, 2025, Immunovia AB (publ)'s estimated intrinsic value ranges from $0.00 to $0.00 per share, depending on the valuation methodology applied.

Valuation Method Fair Value (USD) Implied Upside/Downside

Is Immunovia AB (publ) (IMMNOV.ST) undervalued or overvalued?

With the current market price at $0.34, the stock appears to be significantly overvalued.

Understanding Intrinsic Value

Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Immunovia AB (publ)'s intrinsic value, including:

Weighted Average Cost of Capital (WACC)

The cost of capital is a critical factor in valuation models, representing the required return for investors.

WACC Component Low High
Long-term bond rate 2.5% 3.0%
Equity market risk premium 5.1% 6.1%
Adjusted beta 0.32 0.35
Cost of equity 4.7% 6.1%
Cost of debt 7.0% 14.2%
Tax rate 20.6% 20.9%
Debt/Equity ratio 0.01 0.01
After-tax WACC 4.7% 6.2%

Valuation Methods

Key Financial Metrics

Metric Value
Market Capitalization $105M
Enterprise Value $81M
Trailing P/E 0.00
Forward P/E 0.00
Trailing EV/EBITDA 8.05
Current Dividend Yield 62.96%
Dividend Growth Rate (5Y) 0.00%
Debt-to-Equity Ratio 0.01

Investment Decision Framework

To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:

  1. Forecast Certainty: DCF methods rely on long-term projections, while earnings power value focuses on current normalized earnings
  2. Business Model Alignment: Dividend models are more appropriate for mature companies with established dividend policies
  3. Historical Accuracy: How well each method has predicted fair value historically

Valuation Weight Matrix

Valuation Method Weight Weighted Value
Weighted Average 100% $0.00

Investment Conclusion

Based on our comprehensive valuation analysis, Immunovia AB (publ)'s weighted average intrinsic value is $0.00, which is approximately 100.0% below the current market price of $0.34.

Key investment considerations:

  • Strong projected earnings growth (-8221% to -5054% margin)
  • Consistent cash flow generation
  • Conservative capital structure (Debt/Equity of 0.01)

Given these factors, we believe Immunovia AB (publ) is currently significantly overvalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.